Armando López‐Guillermo
YOU?
Author Swipe
View article: A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies Open
Purpose: Subasumstat (TAK-981) is a first-in-class inhibitor of SUMOylation that can engage innate and adaptive immune responses in tumors by enhancing type I IFN (IFNI) production. We conducted a phase I/II dose-escalation/-expansion stud…
View article: Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma Open
We report the outcome of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with varnimcabtagene autoleucel (var‐cel), an academic anti‐CD19 chimeric antigen receptor (CAR) T‐cell product. Patients were included in th…
View article: Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up
Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up Open
Large B‐cell lymphoma (LBCL) accounts for about one‐third of adult lymphoma cases. Diagnosis requires specialized hematopathology laboratories, with immunophenotypic analysis essential for confirming B‐cell lineage and identifying variants…
View article: Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)
Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG) Open
The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective su…
View article: Data from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Data from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group Open
Purpose:This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).Patients and…
View article: Data from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Data from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group Open
Purpose:This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).Patients and…
View article: Supplementary Tables and Figures 1 from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Supplementary Tables and Figures 1 from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group Open
Supplementary Tables and Figures
View article: Supplementary Tables and Figures 1 from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
Supplementary Tables and Figures 1 from Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group Open
Supplementary Tables and Figures
View article: Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112)
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112) Open
Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsacl…
View article: Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma Open
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed by hematopoietic transplan…
View article: Robust identification of conventional and leukemic nonnodal mantle cell lymphomas using epigenetic biomarkers
Robust identification of conventional and leukemic nonnodal mantle cell lymphomas using epigenetic biomarkers Open
Mantle cell lymphoma (MCL) is a B-cell lymphoma whose heterogeneous clinical presentation and evolution seem to be mediated by differences in cell of origin as well as in genetic, epigenetic, and transcriptional profiles.1-4 MCL is current…
View article: Evolutionary dynamics of 1,976 lymphoid malignancies predict clinical outcome
Evolutionary dynamics of 1,976 lymphoid malignancies predict clinical outcome Open
Cancer development, progression, and response to treatment are evolutionary processes, but characterising the evolutionary dynamics at sufficient scale to be clinically-meaningful has remained challenging. Here, we develop a new methodolog…
View article: A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma
A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma Open
Watchful waiting is an acceptable management strategy for advanced‐stage, low tumor burden (LTB) patients with follicular lymphoma (FL). However, the prediction of how long this treatment‐free observation period will last remains imperfect…
View article: The academic point‐of‐care <scp>anti‐CD19</scp> chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (<scp>ARI</scp>‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell <scp>non‐Hodgkin</scp> lymphoma
The academic point‐of‐care <span>anti‐CD19</span> chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (<span>ARI</span>‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell <span>non‐Hodgkin</span> lymphoma Open
Summary Varnimcabtagene autoleucel (var‐cel) is an academic anti‐CD19 chimeric antigen receptor (CAR) product used for the treatment of non‐Hodgkin lymphoma (NHL) in the CART19‐BE‐01 trial. Here we report updated outcomes of patients with …
View article: P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA Open
Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Background: Patients with relapsed or refractory (R/R) follicular lymphoma experience progressively shorter remissions with each successive line of therapy, and the diseas…
View article: P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA Open
Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Varnimcabtagene autoleucel (var-cel, ARI-0001 cells), an academic second generation anti-CD19 CAR T-cell, has been granted hospital exemption use by the…
View article: IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia Open
Chronic lymphocytic leukemia (CLL) has high biological and clinical heterogeneity.1,2 A few prognostic factors are used in clinical practice, including immunoglobulin heavy-chain variable (IGHV) gene somatic hypermutation (SHM) status, chr…
View article: A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial
A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial Open
International audience
View article: Circulating tumour DNA concentration and genetic classification improve risk stratification in newly diagnosed patients with Diffuse Large B‐Cell Lymphoma
Circulating tumour DNA concentration and genetic classification improve risk stratification in newly diagnosed patients with Diffuse Large B‐Cell Lymphoma Open
Introduction: Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease with poor outcomes for the 40% of patients who relapse or are refractory to upfront therapy, and current prognostic tools are unable to identify man…
View article: TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMA
TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMA Open
Introduction: Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma presenting in an immune-privileged site, recently recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). Here, we performe…
View article: IMMUNE PROFILE IN THE PERIPHERAL BLOOD (PB) OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AT DIAGNOSIS AND UPON RELAPSE
IMMUNE PROFILE IN THE PERIPHERAL BLOOD (PB) OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AT DIAGNOSIS AND UPON RELAPSE Open
Introduction: FL is characterized by a heterogeneous clinical course. The biologic importance of the tumour microenvironment in FL pathogenesis is well established. However, detailed information on the immune profile in PB has not been pre…